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INTRODUCTION
Pheochromocytoma and paraganglioma are neuroendo-
crine tumors that can cause hypertension, anxiety, and pal-
pitations, and are considerations in the evaluation of second-
ary causes of hypertension.1 Medications used to control 
mood disorders, especially selective serotonin and norepi-
nephrine reuptake inhibitors (SNRIs), specifically venlafax-
ine, can mimic such neuroendocrine tumors both biochemi-
cally, through elevations in normetanephrine levels, and 
clinically, through elevations in blood pressure and heart rate.
SNRIs increase the activity of serotonin and norepineph-
rine in the brain. Milnacipran HCl (Savella®) is an SNRI that 
is indicated for the management of fibromyalgia in adults; it 
is not indicated for management of depression, although the 
drug is chemically similar to other SNRIs used in treating de-
pression.2 Recent studies, however, have demonstrated the ef-
ficacy of milnacipran in the treatment of major depression.3-5 
In contrast with venlafaxine and duloxetine, which have a 
higher affinity for serotonin than for norepinephrine recep-
tors, milnacipran has a balanced ratio of potency in the inhi-
bition of norepinephrine and serotonin uptake.6 Adverse ef-
fects of milnacipran most commonly include nausea (37%), 
headache (18%), constipation (16%), hot flush (12%), and 
insomnia (12%).7,8 Other side effects of serotonin syndrome 
and increased suicidal behavior, especially in the young 
age group, are similar to antidepressants of the same class.
We describe a patient with resistant hypertension on mil-
nacipran. This case revealed the relationship between milnacip-
ran use and hypertension through elevation of catecholamines.
CASE REPORT
A 64-year-old female with uncontrolled hypertension, 
type 2 diabetes, and hyperlipidemia was seen in the endo-
crinology clinic after her primary care physician raised a 
question of a possible pheochromocytoma. Her symptoms 
had gotten worse over a period of five years and included 
palpitations, hyperhidrosis, headaches, anxiety, and dizzi-
ness with standing. The patient had been taking milnacip-
ran for several years for the treatment of severe fibromyalgia. 
Prior to this presentation, she had a five-year work-up for 
secondary causes of hypertension after holding milnacipran 
for a few weeks, including aldosterone to renin ratio and thy-
roid function tests; all results were normal (Table 1). She had 
a modestly elevated 24-hour urine for normetanephrines at 
1381 with normal urinary metanephrines (Table 1). A clonidine 
suppression test was normal, with a suppression rate greater 
than 50%. CT of the abdomen and pelvis was unremarkable. 
Repeat studies in the endocrinology clinic, while she was on 
milnacipran, revealed elevated plasma normetanephrine as well 
as elevated 24-hour urine norepinephrine and normetaneph-
rines with the other labs unremarkable (Table 1). After these lab 
results, a metaiodobenzylguanidine (MIBG) scan and CT scan 
of the abdomen and pelvis showed no evidence of pheochro-
mocytoma. Therefore, a PET scan was obtained as a localiza-
tion study for a pheochromocytoma or a paraganglioma; the 
scan came back negative. It was concluded that, in the setting of 
normal PET, CT, and MIBG scans, the likely source of elevated 
normetanephrines, and probable cause of worsening hyperten-
sion, dizziness, palpitations, and sweating was milnacipran.
DISCUSSION
Serotonin norepinephrine reuptake inhibitors commonly are 
prescribed as therapy for depression and for fibromyalgia.9,10 
The three SNRIs approved in the United States are venlafax-
ine, duloxetine, and milnacipran. Although venlafaxine and 
duloxetine have a 30- and 10-fold selectivity, respectively, for 
serotonin, milnacipran is nonselective in blocking the uptakes 
of norepinephrine and serotonin.11 In our case, a neuroendo-
crine tumor (e.g., a pheochromocytoma or a paraganglioma) 
was ruled out through serology and imaging. Specifically, CT 
scanning has a sensitivity of greater than 93% in the detection of 
pheochromocytomas and a specificity of 95% in the diagnosis 
of these tumors.12 Whereas for MIBG, sensitivity is 86 - 90% for 
pheochromocytomas (especially in extra-abdominal tumors); 
specificity is as high as 99% with I-MIBG and is higher with I-
MIBG (90% sensitivity, 100% specificity).12,13 CT of the abdomen 
and MIBG showed no evidence of pheochromocytoma in our 
case. In addition, PET scan has 78% sensitivity for nonmeta-
static pheochromocytomas and 76% sensitivity for metastatic 
pheochromocytomas, and is considered the best means of lo-
calizing primary pheochromocytomas and ruling out metasta-
ses.12 The PET scan was negative in our case.
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Table 1. Labs obtained by primary care and endocrinology.
Labs First Set Second Set 
Plasma Norepinephrine 590 (ref 0-874)
Plasma Epinephrine 29 (ref 0-62)
Plasma Dopamine < 30 (ref 0-48)
Urine Normetanephrine 502
24-hour Urine 
Normetanephrine 1381 (ref 82-500) 2251 (ref 82-500)
Urine Metanephrine 33
24-hour Urine 
Metanephrine 91 (ref 45-290) 81 (ref 45-290)
Urine Epinephrine 1
24-hour Urine 
Epinephrine 3 (ref 0-20) 6 (ref 0-20)
Urine Norepinephrine 60
24-hour Urine 
Norepinephrine 78 (ref 0-135) 165 (ref 0-135)
Urine Dopamine 131
24-hour Urine Dopamine 360 (ref 0-510) 74 (ref 0-510)
24-hour Urine Free 
Cortisol 11 (ref 0-50)
Free T4 1.22 (ref 0.7-1.71)
Total T3 156 (ref 80-181)
TSH 1.263 (ref 0.4-4) 1.418 (ref 0.35-5)
Plasma Metanephrine < 0.2 (ref < 0.5)
Plasma Normetanephrine 1.2 (ref < 0.9)
24-hour Urine VMA 4 (ref 0-7.5)
24-hour Urine Creatinine 1189 (ref 500-2000) 1340 (ref 500-2000)
Patients generally tolerate SNRIs well and milnacipran 
has an excellent cardiovascular safety profile with little effect 
on electrophysiologic values.13,14 Clinical investigators have 
documented very modest increases in heart rate (3 - 5 beats/
min) and systolic pressure (1 - 3 mmHg) in study subjects 
who took 100 to 200 mg of oral milnacipran daily. In rare in-
stances, however, oral milnacipran has caused significant and 
sustained hypertension and tachycardia,9,10 which appeared to 
occur in our patient. Intravenous milnacipran has increased 
heart rate significantly (by approximately 19% in the first 50 
minutes) and systolic blood pressure (by approximately 21% 
in the first 10 minutes).14 For instance, one patient with manic-
depressive psychosis who took 100 mg/d of oral milnacipran 
developed a hypertensive response (blood pressure, 160/100 
mmHg)1; another patient who took 150 mg/d of milnacipran 
developed severe hypertension, but his blood pressure fell to 
acceptable levels when the dose was reduced to 100 mg/d.15 
 One randomized study revealed that fibromyalgia pa-
tients receiving milnacipran had mean increases in blood 
pressure, both systolic and diastolic, by 4 - 5 mmHg, and 
heart rate by 13 - 14 bpm.16 On the other hand, in a three 
year study of milnacipran for the treatment of fibromyal-
gia which included 1227 patients, clinically significant in-
creases in blood pressure or heart rate occurred in ≤ 1.1% of 
patients, whereas nausea (25.9%) and headache (13.4%) were 
the most common events.17 There also were increases in su-
pine blood pressure (+4/3 mmHg) and heart rate (+5 bpm).17 
 The proposed mechanism of hypertension from SNRIs is in-
creased vascular resistance, mediated by increased noradren-
ergic neurotransmission secondary to greater availability of 
norepinephrine at the postjunctional receptor.1 This increase in 
noradrenergic neurotransmitters associated with SNRIs is sup-
ported further in a case of Tako Tsubo cardiomyopathy which 
was reported in a patient after an overdose of the SNRI, venla-
faxine.18 In that case, the urinary collection showed an elevated 
norepinephrine of 122 µg/24 h (normal level < 100 µg/24 h), 
comparable to our case, indicating that milnacipran can be as-
sociated with this noradrenergic response manifested by wors-
ening hypertension, tachycardia, palpitations, and dizziness. 
 In another prospective study, plasma normetanephrine 
levels were increased in four patients receiving either venla-
faxine or desvenlefaxine, including one patient with a level 
of 8800 pmol/L,19 which further reinforces the correlation be-
tween the SNRI, specifically milnacipran in our case, and el-
evated catecholamines, namely normetanephrines. In one 
study comparing milnacipran to selective serotonin reup-
take inhibitors (SSRIs) for major depression management, 
milnacipran was associated with a higher incidence of head-
ache, dry mouth, and dysuria,3 with our patient presenting 
with complaints of headaches and dry mouth. The tolerabil-
ity of milnacipran was comparable to that of the SSRIs, with 
a higher incidence of dysuria with milnacipran, and a higher 
frequency of nausea and anxiety with the SSRIs.4 Milnacipran 
may offer clinical advantages over tricyclic antidepressants 
(TCAs) in terms of tolerability, and over SSRIs in terms of ef-
ficacy. In particular, the lack of cardiovascular adverse events 
appears to offer advantages in cases of deliberate overdose.5 
 Our case confirmed that elevated normetanephrine levels 
do not always indicate the presence of pheochromocytoma/
paraganglioma and illustrated that milnacipran use, in particu-
lar, can mimic the symptoms of these neuroendocrine tumors. 
A similar finding was mentioned in a study by Neary et al.20 
which concluded that before blood is drawn to measure cat-
echolamine levels, patients should discontinue all medications 
that could interfere with the results. SNRIs, such as venlafaxine 
(Effexor®), historically, and milnacipran (Savella®), as described 
in our case, could interfere with elevations in neuroendocrine 
hormones and may contribute to worsening blood pressure, 
dizziness, sweating, and palpitations. Therefore, the patient 
was switched to another antidepressant that did not affect 
these hormones and, more recently, the patient reported sig-
nificant improvement in her headaches, palpitations, and diz-
ziness and her blood pressure has been within normal limits.
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